3-Methoxytyramine
|
Basic information |
| Metabolite name | 3-Methoxytyramine |
 | HMDB0000022 |
 |
C05587 |
 |
1669 |
| Synonyms | 3-MT; |
| No. of studies | 7 |
|
Basic information |
| Metabolite name | 3-Methoxytyramine |
| HMDB0000022 |
|
C05587 |
|
1669 |
| Synonyms | 3-MT; |
| No. of studies | 7 |
|
Relationship between 3-Methoxytyramine and depression (count: 7) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Down |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type2 | CUMS + middle dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |